Brief: Biocartis And GeneproDx To Collaborate On Fully Automated ThyroidPrint® Test On Idylla
03/11/2020 07:50
Nov 3 (Reuters) - Biocartis BCART.BR :
* ANNOUNCES IT HAS SIGNED A LICENSE, DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT WITH GENEPRODX, A MOLECULAR
DIAGNOSTICS COMPANY BASED IN SANTIAGO, CHILE
* PARTNERSHIP AIMS AT DEVELOPMENT OF GENEPRODX'S NOVEL
GENOMIC
TEST THYROIDPRINT® ON BIOCARTIS' RAPID AND EASY TO USE MOLECULAR
DIAGNOSTICS PLATFORM IDYLLA™
* DEVELOPMENT OF THE THYROIDPRINT® ON IDYLLA™ WILL BE
INITIATED IN
Q4 2020
Source text for Eikon: urn:newsml:reuters.com:*:nNDL7v4ynP
Further company coverage: BCART.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))
Recent news on Biocartis NV
See all newsBrief: Biocartis Group NV Appoints Randy Polonsky As Chief Financial Officer
Brief: Biocartis Appoints New Chief Business Officer, VP Global Marketing
Brief: Biocartis And Merck To Collaborate
Brief: Biocartis's Secured Creditors Enforced Their Security Over Subsidiaries Shares
Brief: Biocartis Announces Expansion Of Its Collaboration With Apis Assay Technologies